Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S has completed the sale of its U.S. Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for $187.5 million in cash before transaction-related expenses. The Priority Review Voucher was granted by the U.S. Food and Drug Administration following approval of YUVIWEL® (navepegritide) in February 2026.
This Form 6-K is also incorporated by reference into Ascendis Pharma’s existing registration statements on Form S-8 and Form F-3, meaning the information becomes part of those shelf and equity compensation registration documents.
Ascendis Pharma A/S filed a report highlighting Week 182 results from its completed Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. Over three and a half years, TransCon PTH showed sustained efficacy and safety, replicating the actions of natural parathyroid hormone across key organs, including the central nervous system, kidneys, small intestine, and bone.
The trial reported improved quality of life and normalized, stable measures such as urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were maintained while allowing most patients to become independent from conventional therapy using active vitamin D and calcium supplements, based on predefined trial endpoints.
Ascendis Pharma A/S reported 5-year (Week 266) results from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The company states long-term treatment showed sustained efficacy and safety while replicating key systemic actions of natural parathyroid hormone.
The 59-patient trial, mostly post-surgical cases, followed a 4-week randomized, double-blind, placebo-controlled period with a 262-week open-label extension. Ascendis reports that TransCon PTH maintained normalized and stable urine calcium, serum calcium, quality of life, and bone mineral density, enabling independence from conventional active vitamin D and calcium therapy.
Additional measures included renal function by estimated glomerular filtration rate, bone mineral density by DXA, symptom burden via the Hypoparathyroidism Patient Experience Scale, and broader health-related quality of life using the SF-36 survey, alongside safety monitoring of treatment-emergent adverse events and 24-hour urine calcium.
Ascendis Pharma A/S reported granting new equity incentives to employees through a warrant program. On June 9, 2026, the board approved a total of 27,030 warrants under Appendix 1a of the company’s Articles of Association, and amended the Articles to allow this grant.
Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $213.23 per share, matching the closing share price on the grant date. Vesting is time-based: 25% vests on the one-year anniversary of the grant and the remaining 75% vests in equal monthly installments over the following 36 months, subject to continued service and certain earlier-vesting exit events.
After this grant, warrants to subscribe for an additional 1,553,563 shares remain available for future grants under the company’s Articles of Association.
Ascendis Pharma A/S EVP & Chief Financial Officer Scott Thomas Smith made an open-market purchase of 100 Ordinary Shares on June 2, 2026 at $219.00 per share.
Following this transaction, he directly holds 4,367 Ordinary Shares of Ascendis Pharma A/S.
Ascendis Pharma A/S director Jean Jacques Bienaime reported three open-market purchases of Ordinary Shares. On May 29, 2026, he bought a total of 500 shares at prices ranging from $222.30 to $223.76 per share. Following these transactions, he directly holds 600 Ordinary Shares of Ascendis Pharma, with no sales reported in this filing.
Ascendis Pharma A/S Executive Vice President and Chief Financial Officer Scott Thomas Smith executed an open-market purchase of 250 Ordinary Shares on May 29, 2026 at $223.32 per share. Following this transaction, his directly held position increased to 4,267 Ordinary Shares.
Ascendis Pharma A/S executive Scott Thomas Smith, EVP & Chief Financial Officer, has reported his equity holdings in an amended Form 3. He directly holds 4,017 Ordinary Shares.
He also holds Restricted Stock Units covering 9,552, 3,197 and 4,246 underlying Ordinary Shares, which begin vesting on March 1, 2027, with some vesting in two or three equal annual installments. In addition, he holds fully vested, currently exercisable warrants over 14,504, 22,755, 27,000, 45,000 and 45,000 Ordinary Shares at exercise prices ranging from $37.18 to $176.28 per share with expiration dates between 2027 and 2031. The filing lists holdings only and does not show any new purchases or sales.
Ascendis Pharma A/S director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On May 26, 2026, he bought a total of 400 shares in two transactions, at weighted average prices of $236.235 and $239.3675 per share, executed across multiple trades within narrow intraday price ranges.
Janus Henderson Group plc reports beneficial ownership of 3,719,452 American Depositary Shares of Ascendis Pharma A/S. The filing states these shares represent 6.0% of the class and that Janus Henderson's affiliated asset managers hold shared voting and dispositive power over 3,719,452 ADSs. The filing disclaims rights to dividends or sale proceeds associated with the Managed Portfolios.